Advertisement
Singapore markets close in 5 hours 2 minutes

  • Straits Times Index

    3,280.31
    -12.82 (-0.39%)
     

  • Nikkei

    37,721.32
    -738.76 (-1.92%)
     

  • Hang Seng

    17,296.37
    +95.10 (+0.55%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Bitcoin USD

    64,306.53
    -2,284.88 (-3.43%)
     

  • CMC Crypto 200

    1,391.57
    -32.53 (-2.28%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Gold

    2,323.80
    -14.60 (-0.62%)
     

  • Crude Oil

    82.84
    +0.03 (+0.04%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • FTSE Bursa Malaysia

    1,571.12
    -0.36 (-0.02%)
     

  • Jakarta Composite Index

    7,148.91
    -25.62 (-0.36%)
     

  • PSE Index

    6,582.49
    +9.74 (+0.15%)
     

Should You Buy ImmunoGen (IMGN) Ahead of Earnings?

Zacks Equity Research
Updated

Investors are always looking for stocks that are poised to beat at earnings season and ImmunoGen, Inc. IMGN  may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because ImmunoGen is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for IMGN in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 21 cents per share for IMGN, compared to a broader Zacks Consensus Estimate of  a loss of 25 cents per share. This suggests that analysts have very recently bumped up their estimates for IMGN, giving the stock a Zacks Earnings ESP of +15.99% heading into earnings season.

 

ADVERTISEMENT

ImmunoGen, Inc. Price and EPS Surprise

ImmunoGen, Inc. Price and EPS Surprise | ImmunoGen, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that IMGN has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for ImmunoGen and that a beat might be in the cards for the upcoming report.

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.

Click here for Zacks' private trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.